Gut bacteria swap may tame diabetes and thyroid disease
NCT ID NCT07733232
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether a one-time dose of fecal microbiota transplantation (FMT) — taking capsules containing processed donor stool — can improve blood sugar control and reduce thyroid antibodies in adults who have both type 2 diabetes and Hashimoto's thyroiditis. All 38 participants will receive the same FMT treatment and be followed for 24 weeks. The study asks whether restoring gut bacteria can help manage these two conditions at once.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fecal microbiota transplantation (FMT) oral capsules
- What this could lead to
- If it works, this could point toward a new way to manage both blood sugar and autoimmune thyroid disease by restoring gut bacteria.
- What could go wrong
- This is a small, single-arm trial with no placebo group, so results may be due to chance. FMT can also carry risks like infection or digestive upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE THYROID DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your gut bacteria hold the key to protecting your kidneys?
- Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
- Can diabetes disrupt the Brain-Heart link?
- A scent of citrus: could bitter orange oil ease fatigue and aid sleep in diabetes?
- A blood marker may reveal how well diabetes treatments are working
- A simple phone call may help millions with diabetes manage insulin — a trial puts it to the test